tpp why so secret? by Public Citizen (CC BY-NC-SA 2.0) https://flic.kr/p/daKbUD
The government’s public consultation on the Trans Pacific Partnership (TPP) has stopped in Vancouver, Calgary, and Montreal in recent weeks as a growing number of people speak out on the agreement. Tens of thousands have also written to the government on the issue with some beginning to consider trade strategy alternatives.
My weekly technology law column (Toronto Star version, homepage version) argues that the interest in other trade options stems from three developments. First, the TPP may not have sufficient support to take effect since under the terms of agreement both Japan and the United States must be among the ratifying countries. Implementation has been delayed in Japan where politicians fear a political backlash and seems increasingly unlikely in the U.S., where the remaining presidential candidates have tried to outdo one another in their opposition to the deal.
Earlier this month, I appeared before the Standing Committee on International Trade alongside Jim Balsillie to discuss the TPP. My opening statement can be found here and a full transcript of the session here. A second panel of Barry Sookman and Lawrence Herman followed to support the TPP. The following exchange was one of the most noteworthy:
Mr. Sukh Dhaliwal: Do you see any negative impacts of the TPP on an average middle-class Canadian?
The Chair: It’ll have to be a short answer.
Mr. Barry Sookman: I don’t see any.
Mr. Lawrence Herman: I don’t either.
The responses were unsurprising given that supporters simply ignore multiple studies that have found negative impacts. NDP MP Tracey Ramsey picked up on this immediately with a follow-on question:
Critics of trade agreements such as the TPP and the Canada-EU Trade Agreement has emphasized that a key concern is that deals will lead to increased costs for pharmaceutical drugs. At a recent Standing Committee on Health hearing on the development of a national pharmacare program, officials with Health Canada confirmed that they expect prices to increase but remain unsure about how much (hat tip: Blacklock’s Reporter). The exchange came from questions by NDP MP Don Davies:
Mr. Davies: Canada has just signed two trade deals, CETA and the TPP, which have new intellectual property provisions. All the literature and opinions I’ve read indicate that this will delay the introduction of generics to market for some time. I’m seeing estimates of two years as about what it’s going to take. Ms. Hoffman, has the department done some analysis on the likely impact of TPP and CETA, and is it true that those trade deals will likely increase the prices that Canadians pay for pharmaceuticals and add a little bit of mud to that already dirty picture?
Yesterday I appeared alongside Jim Balsillie, former co-CEO of Research in Motion, at the House of Commons Standing Committee on International Trade public consultation on the TPP. There were some interesting exchanges that I will highlight once the transcript is released. My opening remarks are posted below.
Appearance before the House of Commons Standing Committee on International Trade, May 5, 2016
Good morning. My name is Michael Geist. I am a law professor at the University of Ottawa, where I hold the Canada Research Chair in Internet and E-commerce Law. I appear today in a personal capacity representing only my own views.
There is lots to say about the TPP – I have written dozens of articles and posts on the agreement and I am currently working on a book on point – but I have limited time so I’ll focus briefly on four issues.
Earlier this week, I delivered a webinar for the Canadian Association of Business Economics on the implications of the TPP. The talk touched on a wide range of concerns including copyright, privacy, culture, and digital policies. A video of the talk can be found here.